Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

Radiation Oncology

Table 3 PDAC related therapeutic aptamers and aptamers-based drug delivery systems

Targeted therapy	Target	SELEX	Preclinical model	Name	Chemistry	Ref.
Inhibitor	PAUF	Protein	Xenograft model	P12FR2	RNA	[50]
Gemcitabine	EGFR	Protein	In vitro	E07	RNA	[56]
AS1411 on gold nanoparticles (AuNS) as inhibitors	Nucleolin	Designed Aptamer	In vitro	AS1411	DNA	[61]
Doxorubicin; nanoparticles with Folic acid/AS1411	Nucleolin	Designed Aptamer	In vitro	AS1411	DNA	[64]
Doxorubicin	CD71	Protein	In vitro	C2-min	RNA	[58]
5-Fluoro-2′-Deoxyuridine	ALPPL-2	Cell	In vitro	SQ-2	RNA	[65]
Triptolide	Nucleolin	Designed Aptamer	Xenograft model	AS1411	DNA	[69]
C/EBPα -saRNA	HPAC	Cell	Xenograft model	P19/P1	RNA	[55]
C/EBPα -saRNA	CD71	Protein	Mouse model of advanced PDAC	TR14	RNA	[54]
Gemcitabine or 5-fluorouracil (5-FU)	HPAC	Cell	In vitro	P19	RNA	[66]
Inhibitor	Vimentin	Cell	In vitro	P15	RNA	[53]
Inhibitor	PD1	Protein	In vitro	XA-PD1–78	DNA	[52]
Inhibitor	PD-L1	Protein	In vitro	XA-PDL1–82	DNA	[52]
Monomethyl auristatin E (MMAE)	CD71	Protein	In vitro	Waz	RNA	[70]
Monomethyl auristatin E (MMAE)	EGFR1	Protein	In vitro	E07	RNA	[70]
Camptothecin	Tenascin-C	Protein	Xenograft mice	GBI-10	DNA	[95]
Gemcitabine	Nucleolin	Designed Aptamer	Xenograft mice	AS1411	DNA	[63]
Doxorubicin	CD71	Cell	In vitro	XQ-2d	DNA	[93]

ISSN: 1748-717X